Adial Pharmaceuticals Files U.S. Patent for AD04, Potential Protection Through 2045
Adial Pharmaceuticals filed a new U.S. utility patent application for its lead investigational agent AD04, targeting genotyped heavy drinking patients with heightened ondansetron responsiveness and requested Track One prioritized examination. Once granted, the patent is expected to protect AD04 through at least 2045, bolstering the program’s IP and licensing leverage.
1. Patent Application Details
On April 29, 2026, Adial filed a U.S. utility patent application with the USPTO for AD04, its lead genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder in heavy drinkers with specific genotypes.
2. Track One Prioritized Examination
The application includes a request for Track One Prioritized examination to expedite USPTO review, enabling faster patentability insights and a condensed prosecution timeline.
3. Expected Patent Protection
If granted, the patent is expected to extend exclusivity for AD04 through at least 2045, reinforcing the durability of Adial’s core asset and long-term commercial opportunity.
4. Commercial and Licensing Strategy
The strengthened IP position enhances Adial’s negotiating leverage in ongoing licensing discussions and supports early enforcement capabilities as the company advances AD04 toward its next clinical phase.